Cel-Sci announces plans to price public sale of common stock, warrants

Deal sells securities via bookrunners Dawson James Securities, Laidlaw

By Devika Patel

Knoxville, Tenn., April 11 - Cel-Sci Corp. said it plans a public offering of common stock and six-month warrants, which will be conducted on a best-efforts basis.

Dawson James Securities, Inc. and Laidlaw & Co. (UK) Ltd. are the joint bookrunners.

Proceeds will be used for the company's Phase III clinical trial, research and development and general and administrative expenses.

Based in Vienna, Va., Cel-Sci develops treatments for cancer and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.